Transcriptional adaptation of Mycobacterium tuberculosis that survives prolonged multi-drug treatment in mice

Elizabeth A Wynn,Christian Dide-Agossou,Matthew Reichlen,Karen Rossmassler,Reem Al Mubarak,Justin J Reid,Samuel T Tabor,Sarah E M Born,Monica R Ransom,Rebecca M Davidson,Kendra N Walton,Jeanne B Benoit,Amanda Hoppers,Dorothy E Loy,Allison A Bauman,Lisa M Massoudi,Gregory Dolganov,Michael Strong,Payam Nahid,Martin I Voskuil,Gregory T Robertson,Camille M Moore,Nicholas D Walter

DOI: https://doi.org/10.1128/mbio.02363-23

IF: 6.4

2023-12-19

mBio

Abstract:A major reason that curing tuberculosis requires prolonged treatment is that drug exposure changes bacterial phenotypes. The physiologic adaptations of Mycobacterium tuberculosis that survive drug exposure in vivo have been obscure due to low sensitivity of existing methods in drug-treated animals. Using the novel SEARCH-TB RNA-seq platform, we elucidated Mycobacterium tuberculosis phenotypes in mice treated for with the global standard 4-drug regimen and compared them with the effect of the same regimen in vitro. This first view of the transcriptome of the minority Mycobacterium tuberculosis population that withstands treatment in vivo reveals adaptation of a broad range of cellular processes, including a shift in metabolism and cell wall modification. Surprisingly, the change in gene expression induced by treatment in vivo and in vitro was largely similar. This apparent "portability" from in vitro to the mouse provides important new context for in vitro transcriptional analyses that may support early preclinical drug evaluation.